BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27317766)

  • 1. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.
    Somers K; Chudakova DA; Middlemiss SM; Wen VW; Clifton M; Kwek A; Liu B; Mayoh C; Bongers A; Karsa M; Pan S; Cruikshank S; Scandlyn M; Hoang W; Imamura T; Kees UR; Gudkov AV; Chernova OB; Haber M; Norris MD; Henderson MJ
    Oncotarget; 2016 Jul; 7(29):46067-46087. PubMed ID: 27317766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
    Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung M; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ
    Oncogene; 2019 May; 38(20):3824-3842. PubMed ID: 30670779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
    Chen L; Deshpande AJ; Banka D; Bernt KM; Dias S; Buske C; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Leukemia; 2013 Apr; 27(4):813-22. PubMed ID: 23138183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
    Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
    Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
    Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
    Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
    Urtishak KA; Edwards AY; Wang LS; Hudome A; Robinson BW; Barrett JS; Cao K; Cory L; Moore JS; Bantly AD; Yu QC; Chen IM; Atlas SR; Willman CL; Kundu M; Carroll AJ; Heerema NA; Devidas M; Hilden JM; Dreyer ZE; Hunger SP; Reaman GH; Felix CA
    Blood; 2013 Apr; 121(14):2689-703. PubMed ID: 23393050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.
    van der Linden MH; Willekes M; van Roon E; Seslija L; Schneider P; Pieters R; Stam RW
    Cell Cycle; 2014; 13(5):834-44. PubMed ID: 24736461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Acetyltransferase Activity of MOF Is Required for
    Valerio DG; Xu H; Chen CW; Hoshii T; Eisold ME; Delaney C; Cusan M; Deshpande AJ; Huang CH; Lujambio A; Zheng YG; Zuber J; Pandita TK; Lowe SW; Armstrong SA
    Cancer Res; 2017 Apr; 77(7):1753-1762. PubMed ID: 28202522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear FGFR2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates
    Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Cattaneo F; Ammendola R; Esposito G
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel infant acute lymphoblastic leukemia cell line with MLL-AF5q31 fusion transcript.
    Imamura T; Morimoto A; Ikushima S; Kakazu N; Hada S; Tabata Y; Yagi T; Inaba T; Hibi S; Sugimoto T; Imashuku S
    Leukemia; 2002 Nov; 16(11):2302-8. PubMed ID: 12399976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma.
    Ahlmann M; Meyer C; Marschalek R; Burkhardt B; Koehler G; Klapper W; Juergens H; Rossig C
    Eur J Haematol; 2014 Oct; 93(4):349-53. PubMed ID: 24635731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.
    Andersson AK; Ma J; Wang J; Chen X; Gedman AL; Dang J; Nakitandwe J; Holmfeldt L; Parker M; Easton J; Huether R; Kriwacki R; Rusch M; Wu G; Li Y; Mulder H; Raimondi S; Pounds S; Kang G; Shi L; Becksfort J; Gupta P; Payne-Turner D; Vadodaria B; Boggs K; Yergeau D; Manne J; Song G; Edmonson M; Nagahawatte P; Wei L; Cheng C; Pei D; Sutton R; Venn NC; Chetcuti A; Rush A; Catchpoole D; Heldrup J; Fioretos T; Lu C; Ding L; Pui CH; Shurtleff S; Mullighan CG; Mardis ER; Wilson RK; Gruber TA; Zhang J; Downing JR;
    Nat Genet; 2015 Apr; 47(4):330-7. PubMed ID: 25730765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-27a downregulates 14-3-3θ, RUNX1, AF4, and MLL-AF4, crucial drivers of blast transformation in t(4;11) leukemia cells.
    Fioretti T; Zanobio M; Raia M; Errichiello S; Izzo B; Cattaneo F; Ammendola R; Cevenini A; Esposito G
    Cell Biochem Funct; 2022 Oct; 40(7):706-717. PubMed ID: 35981137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement.
    Bueno C; Montes R; Catalina P; Rodríguez R; Menendez P
    Leukemia; 2011 Mar; 25(3):400-10. PubMed ID: 21135858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular findings in childhood leukemia in Brazil: high frequency of MLL-ENL Fusion/t(11;19) in infant leukemia.
    Marques EA; Neves L; Fonseca TC; Lins MM; Pedrosa F; Lucena-Silva N
    J Pediatr Hematol Oncol; 2011 Aug; 33(6):470-4. PubMed ID: 21436736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia.
    Chowdhury T; Brady HJ
    Blood Cells Mol Dis; 2008; 40(2):192-9. PubMed ID: 17905612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression.
    Dou L; Zheng D; Li J; Li Y; Gao L; Wang L; Yu L
    Oncogene; 2012 Jan; 31(4):507-17. PubMed ID: 21706045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.